BioMerieux Settlement Helps Bio-Rad Post 9-Percent Revenue Gain in Q2; Shares Climb 5 Percent

Aug 04, 2006

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories today reported that second-quarter revenue grew 9 percent as net income jumped 75 percent.

The results helped drive up shares in Bio-Rad by more than 5 percent, or $3.30, to $68.43 in mid-afternoon trading.

Receipts for the three months ended June 30 increased to $317.7 million from $291.3 million year over year. The company included a one-time licensing settlement of $11.7 million from bioMérieux.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

The Apple's Journey

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

This Week in Nature

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Change Is Hard to Do

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

Possible Paths for CUP

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Main menu